Hélène Schoemans, Elke Stienissen, Kathy Goris, Susan K Stewart, Meredith Cowden, Kristina Arnahoutova, Steven Z Pavletic, Hildegard Greinix, Anna Barata, Lorna Warwick, Natacha Bolanos, Isabel Barbosa, Guy Bouguet, Isabelle Lhenry-Yvon, Riikka-Leena Manninen, Simona Pavukova, Guy Tavori, Marleen van Amerongen, Anita Lawitschka, Kirk R Schultz, Daniel Wolff, Anne Herrmann
{"title":"Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe.","authors":"Hélène Schoemans, Elke Stienissen, Kathy Goris, Susan K Stewart, Meredith Cowden, Kristina Arnahoutova, Steven Z Pavletic, Hildegard Greinix, Anna Barata, Lorna Warwick, Natacha Bolanos, Isabel Barbosa, Guy Bouguet, Isabelle Lhenry-Yvon, Riikka-Leena Manninen, Simona Pavukova, Guy Tavori, Marleen van Amerongen, Anita Lawitschka, Kirk R Schultz, Daniel Wolff, Anne Herrmann","doi":"10.1016/S2352-3026(24)00357-0","DOIUrl":null,"url":null,"abstract":"<p><p>Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand how to improve the field of GVHD research, management, and care, the cGVHD Eurograft Initiative organised a European community advisory board of patient advocates, with the assistance of the Lymphoma Coalition, to identify unmet needs. We present the results of this project in this Viewpoint, which identify unmet GVHD needs from the patient advocates' perspectives and provide five key actionable themes to improve GVHD management and care. The identified themes were: the need for reliable and tailored information, increased patient empowerment, access to professional dedicated care, optimal emotional support, and attention to the financial implications of GVHD, with improved communication as an overarching theme. This first step in patient-centred research opens the way to future collaborative initiatives by merging stakeholder perspectives to strive for better care and outcomes after HCT by addressing the most pertinent patient needs.</p>","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"12 3","pages":"e214-e223"},"PeriodicalIF":15.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2352-3026(24)00357-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand how to improve the field of GVHD research, management, and care, the cGVHD Eurograft Initiative organised a European community advisory board of patient advocates, with the assistance of the Lymphoma Coalition, to identify unmet needs. We present the results of this project in this Viewpoint, which identify unmet GVHD needs from the patient advocates' perspectives and provide five key actionable themes to improve GVHD management and care. The identified themes were: the need for reliable and tailored information, increased patient empowerment, access to professional dedicated care, optimal emotional support, and attention to the financial implications of GVHD, with improved communication as an overarching theme. This first step in patient-centred research opens the way to future collaborative initiatives by merging stakeholder perspectives to strive for better care and outcomes after HCT by addressing the most pertinent patient needs.
期刊介绍:
Launched in autumn 2014, The Lancet Haematology is part of the Lancet specialty journals, exclusively available online. This monthly journal is committed to publishing original research that not only sheds light on haematological clinical practice but also advocates for change within the field. Aligned with the Lancet journals' tradition of high-impact research, The Lancet Haematology aspires to achieve a similar standing and reputation within its discipline. It upholds the rigorous reporting standards characteristic of all Lancet titles, ensuring a consistent commitment to quality in its contributions to the field of haematology.